Loading
If two drugs extend life equally but one makes patients much sicker, the health system should pay less for the sicker one. Build that into how prices are set.
Health technology assessment uses quality-adjusted life-years in principle, but in oncology practice utilities are poorly measured and toxicity rarely moves the price. The proposal is an explicit tolerability adjustment in pricing and reimbursement: standardised patient-reported tolerability data from trials feed a published formula that discounts the price for excess symptomatic toxicity and time toxicity relative to comparators, with the discount revisited as real-world PRO data accrue.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.